过去一年中添加的文章，按日期排序
Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective
H Saini, PK Gupta, AK Mahapatra, S Rajagopala… - Scientific Reports, 2024 - nature.com
4 天前 - … In this study, we have studied the marker compounds … , EGFR, and TTR were
targeted by 3 bioactive compounds and … Additionally, we checked the mutation frequency of the …
targeted by 3 bioactive compounds and … Additionally, we checked the mutation frequency of the …
[PDF][PDF] Computational analysis identifies withastramonolide and kaempferol as highly potent compounds from Datura stramonium targeting EGFR-TK in non-small cell …
8 天前 - … FDA-and EMAapproved tyrosine kinase inhibitors in advanced EGFRmutated
non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management…
non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management…
[PDF][PDF] … Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges
M Hussain, N Mackrides, S Su, A Seth - Cureus, 2024 - cureus.com
9 天前 - … This case study represents a 69-year-old female with a co-occurring EGFR mutation
… EGFR-TKI, the effects are unknown for rare compound mutations in EGFR, such as EGFR …
… EGFR-TKI, the effects are unknown for rare compound mutations in EGFR, such as EGFR …
Annual change in eGFR in renal hypouricemia: a retrospective pilot study
S Sugihara, Y Yamamoto, K Teramoto… - Clinical and …, 2024 - Springer
11 天前 - … was observed in mean eGFR decline per year and eGFR change rate per year
between the homo/compound heterozygote with URAT1 gene mutation group and wild-type/…
between the homo/compound heterozygote with URAT1 gene mutation group and wild-type/…
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
C Thomson, E Braybrooke, N Colclough… - Journal of Medicinal …, 2024 - ACS Publications
16 天前 - … activity of compound 28 in the EGFR Ex20Ins mutant models when compared to
the activity in the EGFR WT model suggested that compound 28 had a margin to WT EGFR in …
the activity in the EGFR WT model suggested that compound 28 had a margin to WT EGFR in …
Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis
20 天前 - … natural compounds … EGFR) mutation and overexpression, making EGFR an essential
target for lung cancer treatment (38, 39). In order to attach to the ATP-binding site of EGFR …
target for lung cancer treatment (38, 39). In order to attach to the ATP-binding site of EGFR …
[HTML][HTML] Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex
Q Zhu, R Zhang, X Gu, Z Zhao, Q Gao, M Chen… - Theranostics, 2024 - ncbi.nlm.nih.gov
21 天前 - … compounds that are sensitive to KRAS G13D mutation, we … platform with a natural
product compound library. Here, … change of EGFR signaling cascade, phospho-EGFR (pEGFR…
product compound library. Here, … change of EGFR signaling cascade, phospho-EGFR (pEGFR…
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars
F Seiwerth, L Bitar, M Samaržija… - Expert Opinion on …, 2024 - Taylor & Francis
28 天前 - … Bevacizumab is an antiangiogenic compound whose addition to chemotherapy
made … treatment in EGFR mutated NSCLC, compared to first and even second line EGFR TKIs (…
made … treatment in EGFR mutated NSCLC, compared to first and even second line EGFR TKIs (…
Escaping the drug-bias trap: using debiasing design to improve interpretability and generalization of drug-target interaction prediction
PD Zhang, J Ma, T Chen - bioRxiv, 2024 - biorxiv.org
29 天前 - … For the drug compound, we fed the molecular graph 𝐸𝐷 into a three-layer … mutations
identified in non-small cell lung cancer (NSCLC). Researchers categorized EGFR mutants …
identified in non-small cell lung cancer (NSCLC). Researchers categorized EGFR mutants …
Abstract PR-16: Evaluating direct KRASQ61H inhibition in pancreatic cancer models
SA Long, AM Amparo, H Todd, G Goodhart… - Cancer …, 2024 - aacrjournals.org
30 天前 - … -selective inhibitor tool compound. We … EGFR and RAS(ON) inhibition as a
potential therapeutic strategy in the treatment of PDAC patients harboring KRAS Q61H mutations. …
potential therapeutic strategy in the treatment of PDAC patients harboring KRAS Q61H mutations. …